Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics (ALDX) announced the FDA's acceptance of the New Drug Application (NDA) for ADX-2191, aimed at treating primary vitreoretinal lymphoma. The FDA granted Priority Review, with a PDUFA date set for June 21, 2023. ADX-2191 could become the first FDA-approved treatment for this rare cancer, with no approved alternatives currently available. The NDA is supported by extensive literature and recent Phase 3 GUARD Trial data, showing no serious adverse safety signals. Aldeyra plans to launch ADX-2191 in the U.S. in the second half of 2023, pending FDA approval.
Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on March 9, 2023, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2022, and recent corporate highlights. The call is accessible to both domestic and international callers with dedicated dial-in numbers. Investors can also access a live audio webcast of the conference through Aldeyra’s website, where the event will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on therapies for immune-mediated diseases, with key product candidates under FDA review.
Aldeyra Therapeutics (Nasdaq: ALDX) announced positive top-line results from a 12-month safety trial of reproxalap for dry eye disease. The trial, involving 447 patients, showed no treatment-related serious adverse events and similar ocular safety metrics across both reproxalap and vehicle groups. Post-hoc analysis indicated that reproxalap significantly improved distance visual acuity by approximately 37%, marking a potential breakthrough as the first topical treatment to demonstrate such improvement. With over 2,300 patients tested, reproxalap continues to show a promising safety profile, reinforcing its viability for regulatory review.
Aldeyra Therapeutics (Nasdaq: ALDX) announced the advancement of two new drug candidates, ADX-246 and ADX-248, into clinical testing for treating systemic immune-mediated diseases and geographic atrophy, respectively. These candidates are part of Aldeyra's innovative drug discovery platform targeting RASP modulation. Pending completion of FDA requirements, a Phase 1 trial for ADX-246 and a Phase 1/2 trial for ADX-248 are expected to start in late 2023 or early 2024. With over 100 million people in the U.S. facing diseases linked to systemic inflammation, these developments underscore Aldeyra's leadership in this therapeutic area.
Aldeyra Therapeutics (NASDAQ: ALDX) announced the initiation of Phase 2 clinical trials for ADX-629, targeting minimal change disease and Sjögren-Larsson Syndrome. The minimal change disease trial will now also include idiopathic nephrotic syndrome. Additionally, a new trial for atopic dermatitis has commenced. Aldeyra's recent credit facility amendment extends its cash runway into the second half of 2024, positioning the company to advance its product candidates, including reproxalap and ADX-2191, if approved. Top-line results are expected in 2023, showcasing the company's commitment to developing innovative treatment options.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that Dr. Todd C. Brady, President and CEO, will participate in a fireside chat at the SVB Securities Global Biopharma Conference, taking place virtually from February 14-16, 2023. Dr. Brady's discussion with Senior Research Analyst Marc Goodman is scheduled for 10:00 a.m. ET on February 16. Investors can watch the live webcast through Aldeyra's Investors & Media section and the event will be archived for 90 days. Aldeyra is focused on developing therapies for immune-mediated diseases, including potential treatments for dry eye disease and primary vitreoretinal lymphoma.
Aldeyra Therapeutics announced the acceptance of its New Drug Application (NDA) for topical ocular reproxalap by the FDA, with a PDUFA date of November 23, 2023.
The drug aims to address dry eye disease, a condition affecting over 39 million adults in the U.S. The NDA is backed by positive results from five clinical trials, indicating reproxalap's potential for rapid and durable effects. The drug has shown no significant safety concerns in more than 2,000 patients, though mild irritation at the application site was noted. Aldeyra is optimistic about the drug's efficacy and the unmet needs in dry eye disease treatment.
Aldeyra Therapeutics (NASDAQ: ALDX) announced the submission of a New Drug Application (NDA) for ADX-2191, a methotrexate injection for treating primary vitreoretinal lymphoma, a rare cancer with no approved therapy. This NDA is backed by safety data from the Phase 3 GUARD Trial, which showed ADX-2191 was well tolerated, with fewer adverse events compared to compounded methotrexate. The company has also requested Priority Review from the FDA to expedite the process. ADX-2191 also holds FDA Orphan Drug Designation, highlighting its potential significance in treating this condition.
Aldeyra Therapeutics (ALDX) reported promising results from a Phase 2 clinical trial of its investigational drug ADX-629, which showed significant reductions in dermal flushing (P=0.0007) and acetaldehyde levels (P=0.03), alongside improved balance (P=0.02) after alcohol exposure. The findings are particularly significant for patients with alcohol-associated liver diseases, where treatment options are limited. Aldeyra plans to initiate an investigator-sponsored Phase 2 trial for ADX-629 in moderate alcoholic hepatitis in 2023, further exploring its therapeutic potential.
Aldeyra Therapeutics plans to submit a New Drug Application (NDA) for ADX-2191 to treat primary vitreoretinal lymphoma by the end of 2022. The drug has received FDA Orphan Drug Designation and aims to be the first approved therapy for this rare condition, which has a median survival of less than five years. The NDA will include data from the Phase 3 GUARD Trial, which reported no significant safety concerns. Aldeyra also intends to request a Priority Review designation to expedite the FDA review process.